Abstract
ABSTRACTNumerous anti-cancer drugs perturb thymidylate biosynthesis and lead to genomic uracil incorporation contributing to their antiproliferative effect. Still, it is not yet characterized if uracil incorporations have any positional preference. Here, we aimed to uncover genome-wide alterations in uracil pattern upon drug-treatment in human cancer cell-line HCT116. We developed a straightforward U-DNA sequencing method (U-DNA-Seq) that was combined within situsuper-resolution imaging. Using a novel robust analysis pipeline, we found broad regions with elevated probability of uracil occurrence both in treated and non-treated cells. Correlation with chromatin markers and other genomic features shows that non-treated cells possess uracil in the late replicating constitutive heterochromatic regions, while drug treatment induced a shift of incorporated uracil towards more active/functional segments. Data were corroborated by colocalization studies via dSTORM microscopy. This approach can also be applied to study the dynamicspatio-temporalnature of genomic uracil.
Publisher
Cold Spring Harbor Laboratory
Reference69 articles.
1. Genomic and Proteomic Resolution of Heterochromatin and Its Restriction of Alternate Fate Genes
2. A Method for Quantifying Molecular Interactions Using Stochastic Modelling and Super-Resolution Microscopy;Scientific Reports,2017
3. Histone Lysine Methylation Dynamics: Establishment, Regulation, and Biological Impact
4. New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed (’Tomudex’);British Journal of Cancer,1998
5. The recent evolution of human L1 retrotransposons
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献